This inventor holds 3 USPTO granted patents and 1 published patent application, plus 3 CIPO patents. Top assignees: Mogam Institute for Biomedical Research, The Green Cross Corporation. Active years: 2022-2025.
Company Filing History:
3 out of 17 
3 out of 264 
Years Active: 2022-2025
Title: Innovations of Jong Wha Won in Cancer Treatment
Introduction
Jong Wha Won is a notable inventor based in Yongin-si, South Korea, recognized for his contributions to cancer treatment through innovative antibody technologies. With a total of three patents, his work focuses on developing bispecific antibodies that target specific cancer markers.
Latest Patents
One of his latest patents is titled "Bispecific antibody specifically binding to GPNMB and CD3, and use thereof." This invention describes a bispecific anti-GPNMB/anti-CD3 antibody that specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B). The antibody demonstrates high affinity and specificity for both targets, effectively inducing death in cancer cells that express GPNMB while inhibiting their proliferation. This bispecific antibody holds promise as an effective therapeutic agent for cancers that express GPNMB. Another significant patent is "Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same." This invention relates to an anti-CD3 antibody that has high affinity and specificity for CD3, making it a valuable tool in cancer prevention and treatment.
Career Highlights
Jong Wha Won has worked with prominent organizations in the biomedical field, including the Green Cross Corporation and Mogam Institute for Biomedical Research. His experience in these institutions has contributed to his expertise in antibody development and cancer research.
Collaborations
Some of his notable coworkers include Eun Jung Song and Ok Jae Lim, who have collaborated with him on various projects related to his innovative research.
Conclusion
Jong Wha Won's innovative work in developing bispecific antibodies represents a significant advancement in cancer treatment. His patents reflect a commitment to improving therapeutic options for patients suffering from cancer.